<DOC>
	<DOC>NCT01277133</DOC>
	<brief_summary>This single arm, prospective, observational study will assess the correlation between the time from start of chemotherapy to the start of Avastin (bevacizumab) treatment with progression-free survival in patients with previously untreated metastatic breast cancer. Patients will be followed for up to 12 months after progressive disease occurs.</brief_summary>
	<brief_title>An Observational Study on The Correlation Between Time of Initiation of Avastin (Bevacizumab) Treatment And Progression-Free Survival in Patients With Metastatic Breast Cancer (CRONOS 2)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Previously untreated metastatic breast cancer Scheduled to start 1st line chemotherapeutic treatment ECOG performance status 01 Any conditions included in contraindication list for Avastin Prior chemotherapy for metastatic breast cancer Adjuvant/neoadjuvant chemotherapy or radiochemotherapy of nonmetastatic malignancy completed &lt;6 months prior to treatment start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>